Management Summary
- Purpose / Background: The IA has observed a significant surge in the use of premium financing (PF) for long-term insurance policies, often becoming a primary source of new business. This trend creates risks, including aggressive lapse behavior, liquidity stress on participating funds, and potential misalignment between policyholder expectations and product design.
- One-line conclusion: Insurers must urgently review their product governance, ORSA frameworks, and sales disclosures to ensure that risks associated with high PF concentration and leverage are explicitly identified, managed, and disclosed.
- Key Changes:
- Heightened expectation for formal assessment of PF concentration within product governance (GL16).
- Requirement to include PF-specific risk analysis (lapse, liquidity, conduct, and concentration) in ORSA reports (GL21).
- Mandatory enhancement of stress testing to include PF-specific economic and lapse scenarios.
- Stricter oversight on promotional materials to ensure balanced disclosure of downside risks (e.g., interest rate volatility, leverage impact).
- Key Dates / Deadlines:
- Ongoing compliance requirement; Joint IA/HKMA inspections scheduled for H2 2026.
- Applicability / Impact scope: All authorized insurers carrying on long-term insurance business in Hong Kong, particularly those with high volumes of premium-financed policies.
- Recommended management actions:
- Conduct a portfolio-wide review of PF concentration and update product design/pricing assumptions where necessary.
- Perform a gap analysis on the current ERM/ORSA framework to ensure PF risks are adequately captured.
- Audit all current sales and training materials to ensure "downside risks" are as prominent as leveraging benefits.
- Enhance stress testing models to simulate non-linear lapse behaviors in PF-heavy blocks.
- Ensure remedial action plans are documented and ready for inspection.
Detailed Summary
1) Document overview
This circular addresses the rising prevalence of premium financing in long-term insurance and its potential to cause systemic risks to policyholder outcomes and insurer liquidity. It reinforces existing obligations under GL16 (Underwriting) and GL21 (ERM).
2) Main requirements
- Product Governance: Insurers must assess if product design, pricing, and non-guaranteed benefit determinations remain fair when a high proportion of sales are PF-driven.
- ERM & ORSA: Where PF is a dominant component, it must be integrated into the ORSA process. This includes quantifying risks like lapse, concentration, and liquidity.
- Sales Practices: Marketing materials must avoid over-emphasizing leverage. Benefits must be balanced with clear disclosures of downside risks, including potential borrowing cost increases and adverse policy performance.
3) Key changes
- Increased scrutiny on "Day 1" surrender values and premium discounts, which may incentivize short-term interest rate arbitrage.
- Shift from general risk assessment to specific PF-focused stress testing and scenario analysis.
- Explicit prohibition of using non-guaranteed benefit reductions as a "primary" mitigation tool for pricing/assumption mismatches.
4) Important dates & transition
- Immediate effect: All insurers are expected to align practices with these reminders.
- Monitoring phase: Joint IA/HKMA inspections scheduled for H2 2026.
5) Impact and risks
- Operational: Increased requirements for documentation of product reviews and monitoring of sales practices.
- Financial: Potential need for capital adjustments or repricing if current assumptions do not account for observed high-lapse behaviors in PF policies.
- Conduct: Risk of regulatory sanction if disclosures are found to be misleading or "tactfully" biased toward leverage.
6) Compliance action checklist
- [ ] Review current PF concentration levels by product.
- [ ] Document justification for existing lapse assumptions in PF-heavy products.
- [ ] Update sales/training scripts to explicitly highlight the "downside" of leverage.
- [ ] Enhance the ORSA report to feature a dedicated section on PF stress and scenario analysis.
- [ ] Ensure all remedial actions are documented for future IA/HKMA inspections.
7) Appendices/attachments summary
- *Note: This document acts as a standalone regulatory circular and does not contain formal, separate appendix documents.*